---
layout: post
title: New Drug Approvals 2014 - Pt. VI - Florbetaben F18 (Neuraceq™)
date: '2014-05-14T12:53:00.000+01:00'
author: Gerard JP van Westen
tags:
- Small Molecule Drugs
- Black Box Warning Drugs
- 2014 New Drugs
modified_time: '2014-05-14T12:53:44.451+01:00'
thumbnail: http://3.bp.blogspot.com/-NwiuB_FjRHg/U3DIrtBHaJI/AAAAAAAAPkY/YoIsvXBRJM4/s72-c/neuraceq.png
blogger_id: tag:blogger.com,1999:blog-2546008714740235720.post-6895581402699232994
blogger_orig_url: http://chembl.blogspot.com/2014/05/new-drug-approvals-2014-pt-vi.html
---

<div dir="ltr" style="text-align: left;" trbidi="on">
<div class="separator" style="clear: both; text-align: center;">
<a href="http://3.bp.blogspot.com/-NwiuB_FjRHg/U3DIrtBHaJI/AAAAAAAAPkY/YoIsvXBRJM4/s1600/neuraceq.png" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" src="http://3.bp.blogspot.com/-NwiuB_FjRHg/U3DIrtBHaJI/AAAAAAAAPkY/YoIsvXBRJM4/s1600/neuraceq.png" /></a></div>
<div class="separator" style="clear: both; text-align: center;">
<br /></div>
<div class="separator" style="clear: both; text-align: center;">
<br /></div>
<div class="separator" style="clear: both; text-align: center;">
<a href="https://www.ebi.ac.uk/chembltools/autoiconlarge2/1,1,0,1,0,0,1,0,1,1" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" height="41" src="https://www.ebi.ac.uk/chembltools/autoiconlarge2/1,1,0,1,0,0,1,0,1,1" width="400" /></a></div>
<div style="text-align: center;">
<b><br />
</b><b>ATC Code:&nbsp;</b>Unavailable</div>
<div style="text-align: center;">
<b>Wikipedia:</b>&nbsp;<a href="http://en.wikipedia.org/wiki/Florbetaben_F18">Florbetaben_F18</a></div>
<div style="text-align: center;">
<b>ChEMBL:&nbsp;</b><a href="https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1908906">CHEMBL1908906</a></div>
<br />
On March 19th the <a href="http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Label_ApprovalHistory#apphist">FDA approved</a> <a href="http://en.wikipedia.org/wiki/Florbetaben_F18">&nbsp;Florbetaben F18</a> (Neuraceq™) as a radioactive diagnostic agent for Positron Emission Tomography (PET) imaging of the brain to estimate <a href="http://en.wikipedia.org/wiki/Beta_amyloid">β-amyloid</a> (βA) neuritic plaque density in adult patients with cognitive impairment who are being evaluated for<a href="http://en.wikipedia.org/wiki/Alzheimer's_disease"> Alzheimer’s disease</a> or other causes of cognitive decline.<br />
<br />
Alzheimer's disease is the most common form of dementia, can currently not be cured and is characterised by a progressive disease pattern that usually leads to death. &nbsp;Alzheimer's is predicted to affect 1 in 85 people globally <a href="http://un.org/esa/population/publications/wpp2006/WPP2006_Highlights_rev.pdf">by 2050</a>.<br />
<br />
<b>Target(s)</b><br />
Florbetaben <a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2593886/">binds with high affinity to&nbsp;βA</a>&nbsp;in brain homogenates and selectively labels βA plaques and cerebral amyloid angiopathy. βA (<a href="http://www.ebi.ac.uk/pdbe-srv/PDBeXplore/pfam/?pfam=PF03494">PDB</a>&nbsp;; Uniprot&nbsp;<a href="http://www.uniprot.org/uniprot/P05067">P05067</a>) denotes 36-43 length peptides that are believed to be crucially involved in the Alzheimer's disease mechanism.&nbsp;βA&nbsp;aggregates in the brain of Alzheimer's patients and is derived from <a href="http://en.wikipedia.org/wiki/Amyloid_precursor_protein">amyloid precursor protein</a> which is cut by certain enzymes. βA and the resulting plaques are toxic to neurons. Following intravenous administration,&nbsp;Florbetaben F18&nbsp;crosses the blood&nbsp;brain barrier and shows differential retention in brain regions that contain&nbsp;βA&nbsp;deposits. Differences in signal intensity between brain regions showing specific and non­ specific&nbsp;Florbetaben F18&nbsp;uptake form the basis for the image interpretation method.<br />
<div>
<br /></div>
<br />
<div class="separator" style="clear: both; text-align: center;">
<a href="http://4.bp.blogspot.com/-7KdO1yMjdzA/U3DPN64zAVI/AAAAAAAAPkw/Xg0wP7EHfpI/s1600/Screen+Shot+2014-05-12+at+14.39.53.png" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" src="http://4.bp.blogspot.com/-7KdO1yMjdzA/U3DPN64zAVI/AAAAAAAAPkw/Xg0wP7EHfpI/s1600/Screen+Shot+2014-05-12+at+14.39.53.png" height="186" width="400" /></a></div>
<div class="separator" style="clear: both; text-align: left;">
<br /></div>
<div class="separator" style="clear: both; text-align: center;">
<span style="text-align: left;">Florbetaben F18 (</span><a href="https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1908906">CHEMBL1908906</a>;&nbsp;<span style="text-align: left;">Pubchem :&nbsp;<a href="http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=53257383">53257383</a></span><span style="text-align: left;">) is a small molecule drug with a molecular weight of 359.4 Da, an AlogP of 3.75, 12 rotatable bonds, and no rule of 5 violations. Florbetaben F18&nbsp;</span></div>
<div class="separator" style="clear: both; text-align: center;">
<span style="text-align: left;">is administered intravenously.</span></div>
<div class="separator" style="clear: both; text-align: center;">
<br /></div>
<b>Canonical SMILES</b>:&nbsp;CNc1ccc(\C=C\c2ccc(OCCOCCOCCF)cc2)cc1<br />
<b>InChi</b>: InChI=1S/C21H26FNO3/c1-23-20-8-4-18(5-9-20)2-3-19-6-10-21(11-7-19)26-17-16-25-15-14-24-13-12-22/h2-11,23H,12-17H2,1H3/b3-2+<br />
<div>
<br /></div>
<div>
<b>Dosage</b></div>
<div>
<div>
The recommended dose of Neuraceq is 300 MBq (8.1 mCi), maximum 30 mcg mass dose, administered as a single<br />
<div style="display: inline !important;">
slow intravenous bolus (6 sec/mL) in a total volume of up to 10 mL. PET images should subsequently be acquired approximately 45 - 130 minutes after injection over a period of 15-20 minutes.&nbsp;</div>
</div>
</div>
<div>
<br /></div>
<div>
<div style="display: inline !important;">
<b>Warning / limitations of use</b></div>
</div>
<div>
<div style="display: inline !important;">
<div>
A positive Neuraceq scan does not establish the diagnosis of AD or any other cognitive disorder.</div>
<div>
Safety and effectiveness of Neuraceq have not been established for:</div>
<div>
<ul style="text-align: left;">
<li>Predicting development of dementia or other neurologic conditions;</li>
<li>Monitoring responses to therapies.</li>
</ul>
</div>
<div>
<div>
Neuraceq, similar to other radiopharmaceuticals, contributes to a patient's overall long-term cumulative radiation exposure. Long-term cumulative radiation exposure is associated with an increased risk of cancer.</div>
</div>
<div>
<br /></div>
<div>
<b>Pharmacokinetics</b></div>
<div>
<div>
Ten minutes after intravenous bolus injection of 300 MBq of Neuraceq in human volunteers, approximately 6% of the injected radioactivity was distributed to the brain. Florbetaben F 18 plasma concentrations declined by approximately 75% at 20 minutes post-injection, and by approximately 90% at 50 minutes.</div>
</div>
<div>
<b><br /></b></div>
<div>
<i>Elimination</i></div>
<div>
Florbetaben F18 is mainly eliminated via the hepatobiliary route with a mean half-life of approximately 1 hour.&nbsp;</div>
<div>
<br /></div>
<div>
<i>Metabolism</i></div>
<div>
Forbetaben F18 is metabolized mainly by CYP2J2 and CYP4F2.</div>
<div>
<br /></div>
<div>
<b>License holder</b></div>
<div>
The license holder is&nbsp;<a href="http://www.piramal.com/imaging/">Piramal Imaging</a>, the highlights of the prescribing information can be found&nbsp;<a href="http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/204677s000lbl.pdf">here</a>.</div>
<div style="font-weight: bold;">
<br /></div>
</div>
</div>
</div>
